 1
從人類造血幹細胞進行自然殺手細胞體外無血清誘導增殖技術之研發 II 
Serum-free ex vivo expansion of natural killer cells derived 
from human hematopoietic stem cells (II) 
 
計畫編號：NSC 96－2221－E－080－001 
 
執行期限：96 年 8 月 1 日至 97 年 7 月 31 日 
主  持  人：姚少凌 食品工業發展研究所 
共同  主持人：黃效民   食品工業發展研究所 
計畫參與人員：莊子林 食品工業發展研究所 
 吳美玲   食品工業發展研究所 
 
1. 中文摘要 
人體內自然殺手細胞 (NK 細胞)是一種淋巴細胞，屬於先天性免疫系統的一部份，可
直接殺死癌細胞和被病毒感染的細胞，非特異性地抵抗外來病原與微生物。該細胞主要是
由造血幹細胞分化而來，是近年來極富潛力可以作為細胞免疫療法的細胞。我們實驗室先
前已經成功開發出臍帶血造血幹細胞的體外無血清誘導培養基。本次的研究中，我們把增
殖後的造血幹細胞，進一步誘導為自然殺手細胞。我們也嘗試在不同誘導策略下，比較 NK
細胞表現的差異性。實驗結果顯示，經過 4 周的誘導後，能夠成功誘導出大量具有功能性
的 NK 細胞，該細胞的特性為：具有正確的細胞表面抗原、具有癌細胞毒殺能力與能分泌
干擾素 IFN-γ，並且證實先經過無血清增殖後的造血幹細胞，再誘導為 NK 細胞的方法比直
接從造血幹細胞誘導為 NK 細胞的效力提高很多，因此我們認為該成果將有助於未來臨床
免疫療法的 NK 細胞來源。 
 
Abstract 
Natural killer (NK) cells belong to lymphocytes in human body and they are part of human innate 
immune system. NK cells could kill cancer cells and virus infected cells directly and resist 
foreign pathogens and microorganisms nonspecifically. NK cells are derived from CD34+ 
hematopoietic stem cells (HSCs) which have prosperous potential for cellular immunotherapy. 
Previously, our lab had reported an optimized serum-free medium for ex vivo expansion of 
CD34+ cells from umbilical cord blood (UCB). In this study, NK cells were induced from 
serum-free expanded CD34+ cells. We also tried different strategy to induce NK cells and find the 
best induced conditions. The results showed that after 4 weeks culture, the induced NK cells were 
characterized by surface markers, IFN-γ secretion and cytotoxicity against K562 cells which 
indicated that NK cells derived from the expanded CD34+ cells were more functional. 
Furthermore, the serum-free expanded CD34+ cells had better NK cells differentiation capacity, 
IFN-γ secretion, and cytotoxicity than fresh isolated CD34+ cells. Therefore, these results 
provided a promising resource for clinical immunotherapeutic approaches. 
Keywords: natural killer cells(自然殺手細胞), hematopoietic stem cells(造血幹細胞), 
 3
(Miltenyi Biotec)產生的磁場分離出與磁力微珠接合之CD133+細胞。活體外增殖C34+細胞培
養於24孔盤 (BD Biosciences)，實驗室早期建立之無血清條件下細胞起始密度為每孔5×104
個。培養增殖7天後，進行NK細胞之誘導。 
 
3.2. 生長因子與化學藥品 
使用的人類重組蛋白如下: TPO、SCF、FL、IL-2、IL-3、IL-6、IL-7、IL-12、IL-18、
IL-15、GM-CSF與G-CSF購買自PeproTech公司。牛血清白蛋白 (Bovine serum albumin, 
BSA)、麩醯胺酸 (L-glutamine)、胰島素 (Insulin)、運鐵蛋白 (Transferrin)與2-硫氫乙醇 
(2-mercaptoethanol)購買自Sigma公司。 
 
3.3. 細胞培養液 
    活體外增殖CD34+細胞以IMDM (Iscove’s modified Dulbecco’s medium, HyClone)當作基
礎細胞培養液，包含數種混合的細胞激素 (8.5 ng/ml TPO, 4.1 ng/ml IL-3, 15 ng/ml SCF, 6.7 
ng/ml FL, 0.8 ng/ml IL-6, 3.2 ng/ml G-CSF and 1.3 ng/ml GM-CSF)與血清替代物 (1.5 g/l BSA, 
4.4 µg/ml insulin, 60 µg/ml transferrin and 25.9 µM 2-ME). 誘導NK細胞以RPMI當作基礎細
胞培養液，包含數種混合細胞激素 (25 ng/ml IL-2, 25 ng/ml IL-7, 27.25 ng/ml IL-15, 50.75 
ng/ml SCF and 31.25 ng/ml Flt3), 2 mM L-glutamine與10%胎牛血清 (FBS, HyClone)。 
 
3.4. 從CD133+細胞試管內誘導成NK細胞  
經過1週的培養，增殖後的CD34+細胞藉由小鼠抗人類單株抗體並結合磁力微珠純化出
來，以5 × 104個細胞濃度培養於24孔盤。每周更換NK細胞誘導培養液，並將細胞重新繼代
至每毫升1 × 106細胞數。 
 
3.5. 因子試驗與陡升路徑試驗 
    利用Design-Expert軟體 (Stat-Ease, Inc)最後篩選出細胞激素IL-2、IL-7、IL-15、SCF和
Flt3對NK細胞的培養是必要的，再以軟體是算出的最佳細胞激素濃度比例做不同濃度的細
胞生長測試，比較NK細胞在此5種細胞激素最適合生長的濃度。 
 
3.6. 流式細胞儀分析 
    細胞以CD3單株抗體結合FITC螢光與CD56單株抗體結合PE螢光作雙色性染色。經流式
細胞儀分析，NK細胞會特徵性表現CD56+CD3-，增殖後的 CD34+細胞會表現CD34+CD45+
與較低的散射光反射，CD34的計數準則是根據國際血液學治療與移殖工程學會所制定。利
用CD45結合FITC螢光重複染色樣品或小鼠IgG1抗體結合PE來當對照組，可以進一步提高準
確性。 
 
3.7. 干擾素IFN-γ的分析  
    CD34+細胞經過NK培養液誘導5週後，藉著微粒磁珠將CD56+細胞純化出，以每毫升2 × 
105細胞數濃度培養在24孔盤，刺激干擾素合成的培養液以IMDM當基礎培養基，加入10% 
FBS、100 ng/ml IL-12 與100 ng/ml IL-18。培養72小時後，收集細胞上清液，以干擾素IFN-γ 
ELISA kit做定量 (eBioscience)。 
 
 5
導5周時只有每毫升1.79 × 105細胞濃度 (圖2C)。NK細胞數累積至第6周時分別為1.60 × 107
與1.02 × 107細胞數 (圖2D)。因為兩種誘導NK細胞的方式都是從每毫升5 × 104細胞濃度所
增生分化而成，經過6周培養後，無血清增殖與直接增殖NK細胞分別增加320 ± 26與204 ± 50
倍。 
  
4.2. 因子試驗與陡升路徑試驗 
    因子試驗與陡升路徑試驗是利用 Design-Expert 軟體篩選細胞激素，+1 代表每毫升含
20 ng (奈克)細胞激素，以 25-1 次方作 16 種不同組合之因子試驗做比較 (圖 3A)。 不同因子
試驗所誘導出之 NK 細胞，在 1-9 組數目上幾乎沒有差異，後幾組的細胞激素組合增加後，
可見 NK 細胞數目也有增加的趨勢，在第 16 組試驗 NK16 細胞數突然有明顯地增加 (圖
3B)，證實此 5 種細胞激素 IL-2、IL-7、IL-15、SCF、Flt3 對 NK 細胞生長都有正向的幫助。
經 Design-Expert 軟體所設計的因子試驗得到各細胞激素的比例為 1× IL-2 + 1× IL-7 + 1.09× 
IL-15 + 2.03× SCF + 1.25× Flt-3，以陡升路徑試驗作 14 種不同濃度的試驗，來決定最適合
NK 細胞生長的激素濃度 (圖 3C)， 在第 1-5 組試驗的細胞生長結果，細胞數目都有增加的
趨勢，在第 5 組 NK5 的細胞生長狀況最佳，達到最高峰 (圖 3D)，而第 6 組之後細胞數開
始呈現減少的趨勢，因此我們決定以第 5 組的細胞激素濃度來當作 NK 細胞誘導之最適化
濃度，各細胞激素的比例經修正後每毫升細胞培養液須添加 10 ng/ml IL-2 + 10 ng/ml IL-7 + 
10.9 ng/ml IL-15 + 20.3 ng/m SCF + 1.25 ng/m Flt-3，從實驗結果可以推測，NK 細胞對於細
胞激素的依賴度是很高的。 
 
4.3. 細胞培養液的篩選 
    將增殖後的血液幹細胞分別培養在 IMDM、RPMI、DMEM 與 F12-K 培養液中，加入
10% FBS、2 mM L-glutamine 與我們篩選出最適化的細胞激素，經過 4 周誘導培養後，總
細胞數以 IMDM 培養基條件下能得到最多量的細胞 (圖 4A)。總細胞數經過 NK 細胞百分
比換算後，反而 RPMI 與 F12-K 可以誘導出較高數量和比例的 NK 細胞 (圖 4B)，雖然總細
胞數以 IMDM 為最多，但是 IMDM 誘導 NK 細胞的效力明顯比 RPMI 和 F12-K 培養基差，
所以最後我們選擇以 RPMI 作為我們 NK 細胞誘導的培養基。 
 
4.4. 干擾素IFN-γ的分析 
    干擾素(Interferons)是一群免疫系統所產生的蛋白質，能在細胞間傳遞訊息，刺激細胞
防禦病毒，增加NK細胞的活性，它可以“干擾”病毒的複製，並且具有複雜的免疫調節功能。
很多研究都證實有功能的NK細胞會分泌干擾素來抵禦病毒的感染。我們將體外無血清增殖
CD34+細胞，以NK細胞誘導培養基培養4周，純化出CD56+NK細胞，於培養液加入細胞激
素IL-12與IL-18，培養72小時後，使用酵素結合免疫吸附法 (ELISA)來定量干擾素IFN-γ。
可見細胞經過無血清增殖培養後，平均干擾素IFN-γ濃度可以達到2.7 ng/ml，直接誘導的NK
細胞平均干擾素濃度只有0.05 ng/ml，兩者差異甚大 (圖5A) (P值<0.01)，可以證實我們誘導
NK細胞的方法的確較一般直接誘導的方式具有抵抗病毒防禦的能力。 
     
4.5. K562細胞毒殺試驗 
    測試NK細胞的毒殺試驗，我們選用紅白血癌細胞株 (K562)當作目標細胞。K562因為
缺乏一般細胞都會表現的第一型主要組織相容性抗原 (Major histocompatibility complex 
 7
人類身體中的NK細胞分為2個族群，其中90%人類NK細胞中度表現CD56，即為
CD56dim，高度表現CD16+ (FcγRⅢ)，CD16+會與抗體結合，主導ADCC (antibody dependent 
cell-mediated cytotoxicity ）的作用。具有較高的細胞毒殺能力。 10%NK 細胞為
CD56brightCD16dim或CD56brightCD16-富有製造細胞激素的能力，像是IFN-γ、TNF-β、IL-10、
IL-13和GM-CSF。近年發表的文獻中，從造血幹細胞體外誘導成的NK細胞，幾乎都是表現
CD56brightCD16-，但人體中的NK細胞主要表現CD56dimCD16+，但當CD56brightCD16- NK細
胞，注入小鼠體中或人類的自體移植與異體移植，反而會使CD56dimCD16+ NK細胞增加 
[1]，目前推測CD56brightCD16- NK細胞被認為是形成CD56dimCD16+ NK細胞的前驅細胞，但
卻沒有任何實驗證據能支持這的假說。我們將誘導出的NK細胞，以CD56+微粒磁珠純化後，
培養1周，可見到少數CD56brightCD16- NK細胞分化成CD56brightCD16+ NK細胞，這樣的現象，
目前無法解釋，但我們希望未來能夠分化更多的CD16+ NK細胞，來釐清NK細胞未發現的
誘導路徑。 
 我們將誘導出的 NK 細胞，以 CD56+微粒磁珠純化後，加入細胞激素 IL-12 和 IL-18 刺
激，會激發 NK 細胞釋放炎症干擾素 IFN-γ 並有細胞毒殺的能力，比較增殖與未增殖後的
NK 細胞，相同的細胞批次與細胞數目，增殖後產生的 NK 細胞有較好的毒殺能力與干擾素
IFN-γ產生。無血清增殖培養基的確增加細胞分化生長的能力，也增強細胞的功能特性，我
們懷疑這樣的現象可能是增殖培養基中的細胞激素和 NK 誘導過程中胎牛血清中的成分所
引發。總之，我們利用無血清增殖培養基成功誘導出具功能性的 NK 細胞，未來希望能應
用在臨床上免疫治療的 NK 細胞來源。 
 
7. 文獻 
1. Chan A, et al. (2007) CD56bright human NK cells differentiate into CD56dim cells: role of 
contact with peripheral fibroblasts. J. Immunol. 179, 89-94. 
2. Freud AG and Caligiur MA. (2006). Human natural killer cell development. Immunol. Rev. 
214, 56-72.  
3. Farag SS, et al. (2002). Natural killer cell receptors: new biology and insights into the 
graft-versus-leukemia effect. Blood 100:1935-1947. 
4. Roggeri L, et al. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched 
hematopoietic transplants. Science 295:2097-2100. 
5. Miller JS, et al. (1992). The generation of human natural killer cells from CD34+/DR- 
primitive progenitors in long-term bone marrow culture. Blood 80:2182-2187. 
6. Kim S, et al. (2005). Licensing of natural killer cells by host major histocompatibility 
complex class I molecules. Nature 436, 709-713 (2005). 
7. Kobari L, et al. (2000). In vitro and in vivo evidence for the long-term multilineage (myeloid, 
B, NK and T) reconstitution capacity of ex vivo expanded human CD34+ cord blood cells. 
Exp. Hematol. 28:1470-1480. 
8. Vujanovic NL, et al. (1996). Antitumor functions of natural killer cells and control of 
metastases. Methods 9:394-408. 
9. Yao CL, et al. (2003). Factorial designs combined with the steepest ascent method to 
optimize serum-free media for ex vivo expansion of human hematopoietic progenitor cells. 
Enzyme Microb. Technol. 33:343-352. 
 9
(D) 累積的NK細胞數目。雖然NK細胞的百分比會一直持續增加至第7周，但從CD34+細胞
分化的NK細胞數與累積NK細胞數分別在第4周和第6周達到最大。令人特別注意的是幹細
胞經過無血清培養基增殖1周後純化的CD34+細胞比單純直接經由臍帶血分離出的CD34+細
胞有顯著較高的NK分化能力。 
 
 
圖 3. 因子試驗與陡升路徑試驗。(A) 利用 Design-Expert 軟體篩選細胞激素，+1 代表每毫
升含 20 ng (奈克)細胞激素，以 16 種不同的因子試驗做比較。(B) 不同因子試驗所誘導出
之 NK 細胞數目，在第 16 組試驗 NK 細胞有明顯地增加，可見此 5 種細胞激素對 NK 細胞
的生長都有幫助 (n=3)。 (C) 經 Design-Expert 軟體所設計的因子試驗得到各細胞激素的比
例，以陡升路徑試驗來決定最適合生長的細胞激素濃度。 (D) 在第 5 組試驗 NK5 的細胞
生長狀況最佳 (n=3)。 
 
 
圖 4. 細胞培養液的篩選。將增殖後的血液幹細胞分別培養在 IMDM、RPMI、DMEM 與
F12-K 培養液中，加入 10% FBS、2 mM L-glutamine 與我們篩選出最適化的細胞激素。(A) 
經過 4 周誘導培養後，總細胞數以 IMDM 培養基條件下能得到最多量的細胞 (n=3)。 (B) 總
細胞數經過 NK 細胞百分比換算後，反而 RPMI 與 F12-K 可以誘導出較高數量和比例的 NK
細胞 (n=3)。 
 11
1. 計畫成果自評部份：  
請就研究內容與原計畫相符程度、達成預期目標情況、研究成果之學術或應用價值、是
否適合在學術期刊發表或申請專利、主要發現或其他有關價值等，作一綜合評估。 
 
(1) 研究內容與原計畫內容相符合，並達成預期之目標，可由下表列查核點證明。 
計畫查核點及時程 達成情形 成  果  及  時  程  說  明 
建立自然殺手細胞次
群間的分析系統。
(96.8-96.9) 
符合查核點 確立自然殺手細胞的特定表面抗原—CD56+與CD3－，再進一步
建立次群CD16+與CD16－兩群，並建立 flow cytometry的分析系
統。 
建立自然殺手細胞次
群間的體外毒殺測試
系統。(96.9-96.10) 
符合查核點 實驗結果確定所誘導出的兩群自然殺手細胞具有毒殺K562
癌細胞株的能力。 
篩選自然殺手細胞次
群的誘導增殖之飼養
層細胞取代物組成，並
最適化其濃度。
(96.10-96.12) 
符合查核點 實驗結果顯示在增殖後所得之大量造血幹細胞，可進一步
在特定條件下誘導分化為自然殺手細胞次群，該培養條件
為 IMDM medium 內添加 SCF, Flt-3 ligand, IL-2,IL-7 與
IL-15。 
篩選自然殺手細胞次
群間誘導增殖之必須
細胞激素組成，並最適
化其濃度。(97.12-95.3)
符合查核點 實驗結果顯示延續本所先前所開發之造血幹細胞體外無血
清增殖培養系統，在增殖後所得之大量造血幹細胞，可進
一步在特定條件下誘導分化為自然殺手細胞次群，本實驗
並探討該特定條件的組成與濃度的最適化，以達到體外自
然殺手細胞次群的大量誘導與增殖。 
建立自然殺手細胞次
群體外誘導增殖培養
系統，並放大培養規
模。(97.4-97.6) 
符合查核點 結合基礎培養基、細胞激素配方、血清取代物配方以及培
養策略，完成建構出自然殺手細胞體外誘導增殖培養系
統，並可放大培養規模至 200 ml 以供未來個人化使用。 
撰寫結案報告；期刊發
表；或專利申請(97.7-)
符合查核點 完成結案報告，並發表於國際 SCI 期刊 Stem cells and 
Development 2007(16) 1043-1051。 
(2) 研究成果具有應用之價值，將有助於奠定自然殺手細胞於未來細胞免疫療法應用
的基礎。 
(3) 完成結案報告，並發表於國際 SCI 期刊 Stem cells and Development 2007(16) 
1043-1051。 
(4) 本計畫之主要發現在於證實經過本實驗室先前開發之造血幹細胞無血清增殖系統
所增殖出的造血幹細胞，能夠誘導出更大量且更具功能性之自然殺手細胞，突破
目前免疫療法的瓶頸，於未來臨床上的應用，將具有極大價值。
 13
推廣及運用的價值 
1. 開發自然殺手細胞誘導培養系統 
2. 建立自然殺手細胞增殖培養標準操作條件 
3. 協助國內生技產業在癌症細胞療法的研發領域建立領先地位 
4. 提升國內生技產業在癌症細胞療法的研發層次 
※ 1.每項研發成果請填寫一式二份，一份隨成果報告送繳本會，一份送 貴單位研
發成果推廣單位（如技術移轉中心）。 
※ 2.本項研發成果若尚未申請專利，請勿揭露可申請專利之主要內容。 
※ 3.本表若不敷使用，請自行影印使用。 
from CD34 cells in combination with IL-15 (13,14).
However, it is still unclear if serum-free, ex vivo-ex-
panded CD34 cells could differentiate into functional
NK cells.
We have developed a series of serum-free culture sys-
tems for ex vivo expansion of CD34 cells from UCB
(23,24). CD34 cells were highly expanded in the serum-
free and cytokine-optimized medium developed by a sys-
tematic methodology, including the CD34 cells, hema-
topoietic colony-forming cells (CFCs), and long-term
culture-initiating cells (LTC-ICs). Importantly, engraft-
ment of expanded CD34 cells could reconstitute hema-
topoiesis of the irradiated nonobese diabetic/severe com-
bined immunodeficient (NOD/SCID) mice (25). In this
study, we extended the application of serum-free, ex-
panded HSCs further to induce them to differentiate into
NK cells. NK cells derived from serum-free, expanded
CD34 cells and freshly isolated CD34 cells were com-
pared by their growth kinetics, surface marker expres-
sion, interferon- (IFN- production and cytotoxicity
against K562 cells. Our results revealed that serum-free,
expanded CD34 cells showed a significantly higher NK
cell differentiation potential than freshly isolated CD34
cells and might subsequently serve as an alternative cell
source of immunotherapy.
MATERIALS AND METHODS
Expansion of CD34 cells
UCB was collected and processed as previously de-
scribed (23). Briefly, cord blood of newborns was har-
vested with a standard 250-ml blood bag containing cit-
rate-phosphate-dextrose-adenine anticoagulant (Terumo,
Shibuya-ku, Tokyo, Japan) with informed mothers’ con-
sents and processed within 24 h. Mononuclear cells
(MNCs) were isolated by Ficoll-Paque (1.077 g/ml;
Amersham Biosciences, Uppsala, Sweden) density gra-
dient centrifugation. Subsequently, cord blood CD133
cells were obtained by magnetic cell sorting CD133 mi-
crobeads using the Miltenyi VarioMACS device (Mil-
tenyi Biotec, Bergisch Gladbach, Germany), according to
the manufacturer’s instructions. To expand the CD34
cells ex vivo, CD133 cells were seeded at 5  104 cells
per well in 24-well plates (BD Biosciences, Bedford,
MA) in a serum-free condition as previously established
(23). After 7-day cultivation, the expanded CD34 cells
were purified and set as day 0 for NK cell induction.
Growth factors and chemicals
The following recombinant human growth factors were
used: thrombopoietin (TPO), SCF, FL, IL-2, IL-3, IL-6,
IL-7, IL-12, IL-18, IL-15, granulocyte-macrophage
colony-stimulating factor (GM-CSF), and granulocyte
colony-stimulating factor (G-CSF) were purchased from
PeproTech Inc. (Rocky Hill, NJ). Bovine serum albumin
(BSA), L-glutamine, insulin, transferrin (TF), and 2-mer-
captoethanol (2-ME) were obtained from Sigma (St.
Louis, MO).
Culture medium
Serum-free medium for ex vivo expansion of CD34
cells was prepared with Iscove’s modified Dulbecco’s
medium (IMDM; HyClone, Logan, UT) containing a
cocktail of cytokines (8.5 ng/ml TPO, 4.1 ng/ml IL-3, 15
ng/ml SCF, 6.7 ng/ml FL, 0.8 ng/ml IL-6, 3.2 ng/ml G-
CSF, and 1.3 ng/ml GM-CSF) and serum substitutes (1.5
g/L BSA, 4.4 g/ml insulin, 60 çg/ml transferrin, and
25.9 M 2-ME) (23). NK cell induction medium con-
sisted of IMDM containing a cocktail of cytokines (12.5
ng/ml IL-2, 20 ng/ml IL-7, 40 ng/ml IL-15, 50 ng/ml SCF,
and 50 ng/ml FL), 2 mM L-glutamine, and 10% fetal
bovine serum (FBS; HyClone).
Generation of NK cells from CD34 cells in vitro
After 1 week of culture, the expanded CD34 cells
were purified with magnetic microbeads conjugated to a
monoclonal mouse anti-human CD34 antibody (Miltenyi
Biotec). Purified CD34 cells were suspended into NK
cell induction medium at a density of 5  104 cells per
well in 24-well plates. The induction medium was
changed at weekly intervals, and cell density was deter-
mined and readjusted to 1  106 cells/ml. Freshly iso-
lated CD34 cells from cord blood without serum-free
expansion were induced into NK cells as the control
group.
Flow cytometric analysis of CD34 cells 
and NK cells
Cells were stained with fluorescein isothiocyantate
(FITC)-conjugated CD3 monoclonal antibody (mAb)
(Mitenyi Biotec) and phycoerythrin (PE)-conjugated
CD56 mAb and then subjected to two-color flow cy-
tometry on a FACSCalibur analyzer (Becton-Dickinson,
San Jose, CA). NK cells were characterized as CD56
CD3 cells and expanded CD34 cells were character-
ized as CD34CD45 cells, gated with low side-scatter-
ing according to the CD34 enumeration protocols devel-
oped by the International Society of Hematotherapy and
Graft Engineering (ISHAGE) (26). A replicate sample
was stained with FITC-conjugated CD45 mAb and PE-
conjugated mouse immunoglobulin G1 (IgG1) as the iso-
type control to ensure specificity.
For intracellular perforin staining, 1  106 cells after
5 weeks of incubation in NK cell induction medium were
KAO ET AL.
1044
Technologies, Chantilly, Virginia). The cytotoxicity was
calculated by the following formula:
Cytotoxicity (%) 
RESULTS
Generation of NK cells from expanded 
CD34 cells
CD34 cells have been shown able to differentiate into
mature NK cells under appropriate conditions. After the
 100%
LDH release (Experimental Effector
spontaneous  Target spontaneous)
LDH release (Target maximum
 Target spontaneous)
purification with CD133 microbeads, the average purity
of CD34 cells from UCB was 91.3% as previously de-
scribed (23). The number of CD34 cells exhibited a 27-
fold increase after 1 week of cultivation in the serum-
free condition. The expanded CD34 cells were purified
again with CD34 microbeads to ensure the consistency
of the initial conditions for NK cell induction and the av-
erage purity of CD34 cells was 99.4% (Fig. 1A). The
NK cell population that expressed CD56CD3 was only
1.2% (Fig. 1G), and the intensity of CD56 expression
level was relatively low (102 fluorescent magnitude).
Subsequently, the isolated CD34 cells were cultured in
NK cell induction medium. The results indicated that the
percentage of CD34 cells decreased rapidly to 25.0%
after 1 week of induction (Fig. 1B). After 3 weeks of in-
duction, the percentage of CD34 cells decreased con-
tinuously to 3.9% (Fig. 1C), while the population of
KAO ET AL.
1046
FIG. 2. Growth kinetic analysis of generated NK cells derived from CD34 cells. Purified CD34 cells from serum-free ex
vivo expansion (gray bars and ) and freshly isolation from UCB (open bars and ) were incubated in NK induction medium
(n  7). (A) Total cell density. (B) NK cell percentage. (C) NK cell density. (D) Accumulated NK cell number. Although the
NK cell percentage increased until 7 weeks, the NK cell density and accumulated NK cell number derived from expanded CD34
cells achieved their maximums at week 4 and week 6, respectively. Note that the ex vivo-expanded CD34 cells showed a sig-
nificantly higher differentiation efficiency into NK cells than freshly isolated CD34 cells from UCB.
A B
C D
forin, FasL, and CD16 surface marker analysis were per-
formed to identify and characterize the NK cells differ-
entiated from serum-free, expanded CD34 cells. As
shown in Fig. 3, the induced CD56 cells derived from
serum-free, expanded CD34 cells and freshly isolated
CD34 cells both expressed FasL (both were over 85%
in the population of CD56 cells) but not perforin and
CD16. These results indicated that NK cells generated in
this study were CD56brightCD16 NK cells and expressed
only FasL but not perforin.
IFN- secretion by NK cells
IFN- is one of the immunoregulatory cytokines pro-
duced by functional NK cells and is used for verifying
the differentiation process. After 5 weeks of induction,
generated CD56 cells were purified to test their ability
to secrete IFN-. After 72 h of stimulation with IL-12
and IL-18, CD56 cells derived from serum-free, ex-
panded CD34 cells and freshly isolated CD34 cells
both secreted a significant amount of IFN-, verifying
their NK cell identity. The results showed that CD56
cells derived from serum-free, expanded CD34 cells had
a significantly higher IFN- secretion than CD56 cells
derived from freshly isolated CD34 cells (Fig. 4A;
2.77  1.22 ng versus 0.30  0.11 ng by 2  105 cells).
Cytotoxic activity of generated NK cells
After 5 weeks of induction, the cytotoxicity of gener-
ated NK cells was determined by a K562 cytotoxicity as-
say. The cytotoxic activities of NK cells that were de-
rived from serum-free, expanded CD34 cells against
K562 at E:T ratios of 5:1, 2.5:1, 1.25:1, 0.63:1, and 0.31:1
were 27.0%, 24.0%, 15.1%, 14.4%, and 8.5%, respec-
tively, and those from freshly isolated CD34 cells were
16.7%, 12.5%, 11.3%, 9.9%, and 6.3%, respectively (Fig.
4B). The results showed that CD56 cells derived from
serum-free, expanded CD34 cells had a significantly
higher ability of K562 cytotoxicity than CD56 cells de-
rived from freshly isolated CD34 cells.
DISCUSSION
Previously, we have demonstrated that the number of
CD34 cells from human cord blood were successfully
increased in optimized serum-free condition, and the ex-
panded CD34 cells could restore the hematopoiesis of
lethally irradiated NOD/SCID mice in vivo (23,25).
However, the ex vivo-expanded CD34 cells in serum-
free medium were only demonstrated by the differentia-
tion efficacy of myeloid lineages in vitro and in vivo (23).
In this study, we further investigated if the expanded
CD34 cells could also differentiate into NK cells, which
are one of the lymphoid cell lineages. Many studies have
reported that freshly isolated CD34 cells from bone
marrow or UCB could differentiate into NK cells in vitro
(12–14,20,22). In contrast, CD34 cells manipulated in
this study were induced into NK cells after serum-free
expansion to identify the characteristics of generated NK
cells and compare the efficiency of NK cell differentia-
tion with freshly isolated CD34 cells.
We believe that this is the first report demonstrating
KAO ET AL.
1048
FIG. 4. Biological functions of generated NK cells were as-
sayed by IFN- production and cytotoxicty against K562 cells.
(A) IFN- secretion by generated NK cells in the presence of
IL-12 and IL-18. After 5 weeks of induction in the NK cell in-
duction medium, purified CD56 NK cells derived from serum-
free, ex vivo-expanded CD34 cells (gray bar, n  6) and
freshly isolated CD34 cells (open bar, n  6) were incubated
with medium containing IL-2 and IL-18. After 72 h, cell-free
supernatants were collected and IFN- concentrations were
quantitated by ELISA. (B) Cytotoxicity assay of generated NK
cells. Purified CD56 NK cells induced from serum-free, ex
vivo-expanded CD34 cells (gray bar, n  6) and freshly iso-
lated CD34 cells (open bar, n  6) were incubated with K562
cells at various E:T ratios. Results indicate that NK cells in-
duced from serum-free, expanded CD34 cells showed a higher
concentration of IFN- secretion and higher ability of cytotox-
icity than from freshly isolated CD34 cells. *** The compar-
isons were analyzed by a paired-samples t-test. A value of p 
0.01 was considered a significant difference.
A
B
and insights into the graft-versus-leukemia effect. Blood
100:1935–1947.
2. Vujanovic NL, P Basse, RB Herberman and TL Whiteside.
(1996). Antitumor functions of natural killer cells and con-
trol of metastases. Methods 9:394–408.
3. Wallin RPA, V Screpanti, J Michaëlsson, A Grandien and
H Ljunggren. (2003). Regulation of perforin-independent
NK cell-mediated cytotoxicity. Eur J Immunol 33:2727–
2735.
4. Screpanti V, RPA Wallin, A Grandien and H Ljunggren.
(2005). Impact of FasL-induced apoptosis in the elimina-
tion of tumor cells by NK cells. Mol Immunol 42:495–499.
5. Smyth MJ, E Cretney, JM Kelly, JA Westwood, SEA
Street, H Yagita, K Takeda, ALH van Dommelen, MA
Degli-Esposti and Y Hayakawa. (2005). Activation of NK
cell cytotoxicity. Mol Immunol 42:501–510.
6. Roggeri L, M Capanni, E Urbani, K Perruccio, WD Shlom-
chik, A Tosti, S Posati, D Rogaia, F Frassoni, F Aversa,
MF Martelli and A Velardi. (2002). Effectiveness of donor
natural killer cell alloreactivity in mismatched hematopoi-
etic transplants. Science 295:2097–2100.
7. Whiteside TL and RB Herberman. (1995). The role of nat-
ural killer cells in immune surveillance. Curr Opin Im-
munol 7:704–710.
8. Carson W and M Caligiuri. (1996). Natural killer cell sub-
sets and development. Methods 9:327–343.
9. Colucci F, MA Caligiuri and JP Di Santo. (2003). What
does it take to make a natural killer. Nature Rev Immunol
3:413–425.
10. Gluckman E. (2000). Current status of umbilical cord blood
hematopoietic stem cell transplantation. Exp Hematol
28:1197–1205.
11. Grewal SS, JN Barker, SM Davies and JE Wagner. (2003).
Unrelated donor hematopoietic cell transplantation: mar-
row or umbilical cord blood. Blood 101:4233-4244.
12. Miller JS, C Verfaillie and P McGlave. (1992). The gen-
eration of human natural killer cells from CD34/DR
primitive progenitors in long-term bone marrow culture.
Blood 80:2182–2187.
13. Mrozek E, P Anderson and MA Caligiuri. (1996). Role of
interleukin-l5 in the development of human CD56 natural
killer cells from CD34 hematopoietic progenitor cells.
Blood 87:2632–2640.
14. Yu H, TA Fehniger, P Fuchshuber, KS Thiel, E Vivier, WE
Carson and MA Caligiuri. (1998). Flt3 ligand promotes the
generation of a distinct CD34 human natural killer cell
progenitor that responds to interleukin-15. Blood
92:3647–3657.
15. Giarratana MC, V Verge, C Schmitt, JM Bertho, L Kobari,
C Barret and Douay L. (2000). Presence of primitive lym-
phoid progenitors with NK or B potential in ex vivo ex-
panded bone marrow cell cultures. Exp Hematol 28:46–54.
16. Kobari L, F Pflumio, M giarratana, X Li, M Titeux, B Izac,
F Leteurtre, L Coulombel and L Douay. (2000). In vitro
and in vivo evidence for the long-term multilineage
(myeloid, B, NK and T) reconstitution capacity of ex vivo
expanded human CD34 cord blood cells. Exp Hematol
28:1470–1480.
17. Yu Y, M Hagihara, K Ando, B Gansuvd, H Matsuzawa, T
Tsuchiya, Y Ueda, H Inoue, T Hotta and S Kato. (2001).
Enhancement of human cord blood CD34 cell-derived
NK cell cytotoxicity by dendritic cells. J Immunol
166:1590–1600.
18. Sivori S, C Cantoni, S Parolini, E Marcenaro, R Conte, L
Moretta and A Moretta. (2003). IL-21 induces both rapid
maturation of human CD34 cell precursors towards NK
cells and acquisition of surface killer Ig-like receptors. Eur
J Immunol 33:3439–3447.
19. Nagamura-Inoue T, Y Mori, Z Yizhou, N Watanabe and
TA Takahashi. (2004). Differential expansion of umbilical
cord blood mononuclear cell-derived natural killer cells de-
pendent on the dose of interleukin-15 with Flt3L. Exp
Hematol 32:202–209.
20. Cavazzana-Calvo M, S Hacein-Bey, G De Saint Basile, C
De Coene, F Selz, F Le Deist and A Fischer. (1996). Role
of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell
differentiation from cord blood hematopoietic progenitor
cells and from c transduced severe combined immunode-
ficiency X1 bone marrow cells. Blood 88:3901–3909.
21. Fehniger TA and MA Caligiuri. (2001). Interleukin 15: bi-
ology and relevance to human disease. Blood 97:14–32.
22. Nguyen QH, RL Roberts, BJ Ank, SJ Lin, EK Thomas and
ER Stiehm. (1998). Interleukin (IL)-15 enhances antibody-
dependent cellular cytotoxicity and natural killer activity
in neonatal cells. Cell Immunol 185:83–92.
23. Yao CL, CH Liu, IM Chu, TB Hsieh and SM Hwang.
(2003). Factorial designs combined with the steepest as-
cent method to optimize serum-free media for ex vivo ex-
pansion of human hematopoietic progenitor cells. Enzyme
Microb Technol 33:343–352.
24. Yao CL, IM Chu, TB Hsieh and SM Hwang. (2004). A
systematic strategy to optimize ex vivo expansion medium
for human hematopoietic stem cells derived from umbili-
cal cord blood mononuclear cells. Exp Hematol
32:720–727.
25. Yao CL, YH Feng, XZ Lin, IM Chu and SM Hwang (2006).
Characterization of serum-free ex vivo-expanded hemato-
poietic stem cells derived from human umbilical cord blood
CD133 cells. Stem Cells Dev 15:70–78.
26. Sutherland DR, L Anderson, M Keeney, R Nayar and YI
Chin. (1996). The ISHAGE guidelines for CD34 cell de-
termination by flow cytometry. J Hematother 5:231–239.
27. Cooper MA, TA Fehniger and MA Caligiuri. (2001). The
biology of human natural killer-cell subsets. Trends Im-
munol 22:633–640.
28. Jacobs R, M Stoll, G Stratmann, R Leo, H Link and RE
Schmidt. (1992). CD16 CD56 natural killer cells after
bone marrow transplantation. Blood 79:3239–3244.
29. Carayol G, C Robin, J Bourhis, A Bennaceur-Griscelli, S
Chouaib, L Coulombel and A Caignard. (1998). NK cells
differentiated from bone marrow, cord blood and periph-
eral blood stem cells exhibit similar phenotype and func-
tions. Eur J Immunol 28:1991–2002.
30. Perez SA, PA Sotiropoulou, DG Gkika, LG Mahaira, DK
Niarchos, AD Gritzapis, YG Kavalakis, AI Antsaklis, CN
Baxevanis and M Papamichail. (2003). A novel myeloid-
like NK cell progenitor in umbilical cord blood. Blood
101:3444–3450.
KAO ET AL.
1050

master.img-001.jpg
 Back to paper Zoom: 100% | Fit width | Fit height |  %  Close window 
http://www.liebertonline.com/action/showImage?doi=10.1089/scd.2007.0033&iName=master.img-001.jpg&w=467&h=342 第 1 頁 / 共 2 2008/1/10 下午 05:43:25
master.img-002.png
 Back to paper Zoom: 100% | Fit width | Fit height |  %  Close window 
http://www.liebertonline.com/action/showImage?doi=10.1089/scd.2007.0033&iName=master.img-002.png&w=468&h=2982008/1/10 下午 05:43:39
